Cingulate Inc. Increase (Decrease) in Accounts and Notes Receivable
Cingulate Inc. (CING) reported Increase (Decrease) in Accounts and Notes Receivable of -$18.31 thousand for the 12-month period ending 2025-12-31, per its 10-K filed 2026-03-18.
Financial Statements › Cash Flow › Operating Activities
us-gaap:IncreaseDecreaseInAccountsAndNotesReceivable · last filed 2026-03-18
- Cingulate Inc. increase (decrease) in accounts and notes receivable for the quarter ending 2024-03-31 was -$12.38K.
- Cingulate Inc. increase (decrease) in accounts and notes receivable for the quarter ending 2023-12-31 was $8.79K, a 95.30% decline year-over-year.
- Cingulate Inc. increase (decrease) in accounts and notes receivable for the quarter ending 2023-09-30 was -$29.63K.
- Cingulate Inc. increase (decrease) in accounts and notes receivable for the quarter ending 2023-06-30 was $3.52K.
- Cingulate Inc. increase (decrease) in accounts and notes receivable for fiscal 2025 was -$18.31K, a 256.47% decline from fiscal 2024.
- Cingulate Inc. increase (decrease) in accounts and notes receivable for fiscal 2024 was $11.70K.
- Cingulate Inc. increase (decrease) in accounts and notes receivable for fiscal 2023 was -$219.81K.
- Cingulate Inc. increase (decrease) in accounts and notes receivable for fiscal 2022 was -$455.82K, a 184.65% decline from fiscal 2021.
| Period end | Increase (Decrease) in Accounts and Notes Receivable 3 month | Increase (Decrease) in Accounts and Notes Receivable 6 month | Increase (Decrease) in Accounts and Notes Receivable 9 month | Increase (Decrease) in Accounts and Notes Receivable 12 month |
|---|---|---|---|---|
| 2025-12-31 | -$18.31K 10-K · filed 2026-03-18 | |||
| 2024-12-31 | $11.70K 10-K · filed 2026-03-18 | |||
| 2024-03-31 | -$12.38K 10-Q · filed 2024-05-08 | -$3.59K derived: sum of 2 quarters · filed 2025-03-27 | -$33.22K derived: sum of 3 quarters · filed 2025-03-27 | -$29.71K derived: sum of 4 quarters · filed 2025-03-27 |
| 2023-12-31 | $8.79K derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-27 | -$20.85K derived: sum of 2 quarters · filed 2025-03-27 | -$17.33K derived: sum of 3 quarters · filed 2025-03-27 | -$219.81K 10-K · filed 2025-03-27 |
| 2023-09-30 | -$29.63K derived: 10-Q 9 month − 10-Q 6 month · filed 2023-11-13 | -$26.12K derived: sum of 2 quarters · filed 2023-11-13 | -$228.60K 10-Q · filed 2023-11-13 | -$41.51K derived: sum of 4 quarters · filed 2024-05-08 |
| 2023-06-30 | $3.52K derived: 10-Q 6 month − 10-Q 3 month · filed 2023-08-14 | -$198.96K 10-Q · filed 2023-08-14 | -$11.88K derived: sum of 3 quarters · filed 2024-05-08 | -$104.64K derived: sum of 4 quarters · filed 2024-05-08 |
| 2023-03-31 | -$202.48K 10-Q · filed 2024-05-08 | -$15.40K derived: sum of 2 quarters · filed 2024-05-08 | -$108.16K derived: sum of 3 quarters · filed 2024-05-08 | -$619.42K derived: sum of 4 quarters · filed 2024-05-08 |
| 2022-12-31 | $187.08K derived: 10-K 12 month − 10-Q 9 month · filed 2024-04-01 | $94.32K derived: sum of 2 quarters · filed 2024-04-01 | -$416.94K derived: sum of 3 quarters · filed 2024-04-01 | -$455.82K 10-K · filed 2024-04-01 |
| 2022-09-30 | -$92.76K derived: 10-Q 9 month − 10-Q 6 month · filed 2023-11-13 | -$604.02K derived: sum of 2 quarters · filed 2023-11-13 | -$642.90K 10-Q · filed 2023-11-13 | -$309.71K derived: sum of 4 quarters · filed 2023-11-13 |
| 2022-06-30 | -$511.26K derived: 10-Q 6 month − 10-Q 3 month · filed 2023-08-14 | -$550.13K 10-Q · filed 2023-08-14 | -$216.95K derived: sum of 3 quarters · filed 2023-08-14 | -$140.19K derived: sum of 4 quarters · filed 2023-08-14 |
| 2022-03-31 | -$38.88K 10-Q · filed 2023-05-10 | $294.31K derived: sum of 2 quarters · filed 2023-05-10 | $371.07K derived: sum of 3 quarters · filed 2023-05-10 | $445.47K derived: sum of 4 quarters · filed 2023-05-10 |
| 2021-12-31 | $333.19K derived: 10-K 12 month − 10-Q 9 month · filed 2023-03-10 | $409.95K derived: sum of 2 quarters · filed 2023-03-10 | $484.35K derived: sum of 3 quarters · filed 2023-03-10 | $538.48K 10-K · filed 2023-03-10 |
| 2021-09-30 | $76.76K derived: 10-Q 9 month − 10-Q 6 month · filed 2022-11-14 | $151.16K derived: sum of 2 quarters · filed 2022-11-14 | $205.29K 10-Q · filed 2022-11-14 | |
| 2021-06-30 | $74.40K derived: 10-Q 6 month − 10-Q 3 month · filed 2022-08-11 | $128.53K 10-Q · filed 2022-08-11 | ||
| 2021-03-31 | $54.13K 10-Q · filed 2022-05-12 | |||
| 2020-12-31 | $38.53K 10-K · filed 2022-03-28 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Spero Therapeutics, Inc. (SPRO) | United States | $0.073B | 17.41 |
| Aldeyra Therapeutics, Inc. (ALDX) | United States | $0.074B | -5.57 |
| Lunai Bioworks Inc. (LNAI) | United States | $0.072B | -0.11 |
| PMV Pharmaceuticals, Inc. (PMVP) | United States | $0.071B | -0.95 |
| TENAX THERAPEUTICS, INC. (TENX) | United States | $0.071B | -7.17 |
| PLIANT THERAPEUTICS, INC. (PLRX) | United States | $0.071B | -0.76 |
| OS Therapies Inc (OSTX) | United States | $0.076B | -2.17 |
| Yarrow Bioscience, Inc. (YARW) | United States | $0.070B | |
| Verrica Pharmaceuticals Inc. (VRCA) | United States | $0.076B | -3.39 |
| iBio, Inc. (IBIO) | United States | $0.077B | -2.94 |